We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
5 own
6 watching
Current Price
$14.3
$-0.2
(-1.38%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
114.24M
52-Week High
36.2726
52-Week Low
6.8241
Average Volume
0.1M
Dividend Yield
--
P/E Ratio
--
Market Capitalization114.24M
52-Week High36.2726
52-Week Low6.8241
Average Volume0.1M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Zolmax
1month ago
Greenwich LifeSciences, Inc. (NASDAQ:GLSI Get Rating) CEO Snehal Patel acquired 3,000 shares of the stock in a transaction that occurred on Friday, October 14th. The stock was acquired at an average price of $9.75 per share, for a total transaction of $29,250.00. Following the transaction, the chief...
Business Wire
3 months ago
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the Company), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following: Phase III clinical...
Zolmax
5 months ago
Greenwich LifeSciences, Inc. (NASDAQ:GLSI Get Rating) CEO Snehal Patel acquired 6,774 shares of Greenwich LifeSciences stock in a transaction on Thursday, June 2nd. The shares were purchased at an average cost of $7.38 per share, for a total transaction of $49,992.12. Following the acquisition, the ...
Ticker Report
7 months ago
Greenwich LifeSciences, Inc. (NASDAQ:GLSI Get Rating) insider Frank Joseph Daugherty bought 1,000 shares of the firms stock in a transaction on Monday, April 25th. The stock was purchased at an average cost of $16.25 per share, with a total value of $16,250.00. Following the ...
Zolmax
7 months ago
Greenwich LifeSciences, Inc. (NASDAQ:GLSI Get Rating) insider Frank Joseph Daugherty bought 1,000 shares of Greenwich LifeSciences stock in a transaction dated Monday, April 25th. The stock was purchased at an average cost of $16.25 per share, for a total transaction of $16,250.00. Following the ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$14.3
$-0.2
(-1.38%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00